Retatrutide
Retatrutide is an experimental "triple agonist" peptide currently in Phase 3 clinical trials for obesity and Type 2 diabetes. It is widely considered the most potent weight-loss drug in development, often nicknamed the "Godzilla" of GLP-1s due to its ability to target three different hormone receptors simultaneously. For research use only. Not for human consumption.
The "Triple Agonist" Mechanism
While existing drugs like Ozempic (semaglutide) and Zepbound (tirzepatide) target one or two receptors, Retatrutide activates three:
GLP-1 (Glucagon-like Peptide-1): Reduces appetite and slows stomach emptying.
GIP (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin secretion and fat metabolism.
Glucagon: Increases energy expenditure (calorie burning), which sets it apart from predecessors that primarily focus on hunger suppression.
Weight Loss Comparison
In Phase 2 trials, Retatrutide showed significantly higher weight-loss averages than current FDA-approved options
